ARTES Biotechnology and Midas Pharma signed Cooperation Contract

ARTES announced the col­lab­o­ra­tion with Midas for strate­gic mar­ket­ing oppor­tu­ni­ties. Aim of the coop­er­a­tion is the find­ing of suit­able part­ners for defined phar­ma­ceu­ti­cals projects like vac­cine and phar­ma­ceu­ti­cal tar­get devel­op­ment or trans­fer of Biosim­i­lar processes.

ARTES is spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try where­as Midas is an inde­pen­dent mar­ket­ing and dis­tri­b­u­tion com­pa­ny, which sup­ports clients in find­ing poten­tial part­ners and markets.

We are con­fi­dent, that we could, togeth­er with Midas’ world­wide rep­re­sen­ta­tives, break into new mar­kets. Espe­cial­ly our vac­cine devel­op­ment plat­form Metavax® has strong capa­bil­i­ties. The Metavax® plat­form is suit­able for the devel­op­ment and pro­duc­tion of cost-effec­tive vac­cines and there­fore inter­est­ing for mar­kets where price is an issue”, Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES point­ed out. “The high­ly expand­ed net­work of Midas will open for us new oppor­tu­ni­ties cur­rent­ly in regions where we not yet in. We are very pleased that, with Midas, we have been able to acquire a very com­pe­tent and reli­able partner.”